Imiquimod-induced vitiligo

Dermatology Online Journal

Volumn 13, Issue 2, 2007, Pages

  Al Dujaili, Zeena ^a   Hsu, Sylvia ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INTERCELLULAR ADHESION MOLECULE 1; PIMECROLIMUS; TACROLIMUS; AMINOQUINOLINE DERIVATIVE;

APPLICATION SITE ERYTHEMA; ARTICLE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONDYLOMA; DRUG INHIBITION; DRUG WITHDRAWAL; HUMAN; HUMORAL IMMUNITY; KERATINOCYTE; LANGERHANS CELL; PROTEIN EXPRESSION; SKIN EXAMINATION; VITILIGO; ADULT; CASE REPORT; CHEMICALLY INDUCED DISORDER; CONDYLOMA ACUMINATUM; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; GENITAL SYSTEM DISEASE; MALE; PATHOPHYSIOLOGY; RISK ASSESSMENT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AMINOQUINOLINES; CONDYLOMATA ACUMINATA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GENITAL DISEASES, MALE; HUMANS; MALE; RISK ASSESSMENT; VITILIGO;

EID: 34248196025     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-S11.
2. Brown T, Zirvi M, Cotsarelis G, Gelfand J. Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 2005; 52
3. Dahl MV. An immune response modifier. J Am Acad Dermatol 2000; 43: S1-5.
4. Simsek H, Savas C, Akkiz H et al. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996; 193: 65-66.
5. Nouri K, Busso M, Machler BC. Vitiligo associated with alpha-interferon in a patient with active hepatitis C. Cutis 1997; 60: 289-290.
6. Bernstein D, Reddy K, Jeffers L, et al. Canities and vitiligo complicating interferon therapy for hepatitis C. Am J Gastroenterol. 1995; 90:1176-1177.
7. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R848 and imiquimod. Cell Immunol 1999;191:10-9.
8. Skinner R.B., Jr., Imiquimod. Dermatol Clin 2003; 21: pp 291-300.
9. Wankowicz-Kalinska A, Van den Wijngaard RM, Tigges BJ et al. Immunopolarization of CD4+ and CD8+ to type 1like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683-695.
10. Miller R, Birmachu W, Gerster J, et al. Imiquimod cytokine induction and antiviral activity. Int Antiviral News 1995;3:111-3.
11. Moretti S, Spallanzani A, Amato L et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92.
12. Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol. 1991 Feb;96(2):180-5.
13. Yu HS, Chang KL, Yu CL et al. Alterations in IL-6, IL-8, GMCSF, TNF-a, and INF- α release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997; 108: 527-29.
14. Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocyte macrophage clony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003; 31: 73-78.
15. Rocha IM, Guillo LA. Lipopolysacharide and cytokines induce nitric oxide synthesis and produce nitric oxide in cultured normal human melanocytes. Arch Dermatol Res 2001; 293: 245-248.
16. Burns Jr. RP, Ferbel B, Tomai M, et al. The imidazoquinolones, imiquimod and R-848 induce functional, but not phenotypic, maturation of human Langerhans' cells. Clin Immunol 2000;94:13-23.
17. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans' cells. J Invest Dermatol 2000;114:135-41.
18. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
19. Ongenae K., Van Geel N., Naeyaert J.M., Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
20. Kostovic K., Pasic A., New Treatment modalities for vitiligo: focus on topical immunomodulators. Drugs. 2005; 65: 447-459.
21. Tjioe M., Vissers W. H., Gerritsen M. J., Topical macrolide immunomodulators: a role in the treatment of vitiligo. Am J Clin Dermatol. 2006; 7: 7-12.